multipl
sclerosi
ms
chronic
inflammatori
demyelin
diseas
central
nervou
system
cn
thought
mediat
myelinspecif
cell
wherea
deplet
cell
reduc
format
ms
lesion
deplet
b
cell
strikingli
effect
moreov
b
cell
deplet
inhibit
disabl
progress
ms
subject
younger
year
includ
progress
ms
pm
inde
intrathec
activ
b
cell
differenti
antibodi
ab
produc
counterpart
plasmablast
plasma
cell
hallmark
ms
pathologist
identifi
b
cell
mening
tissu
form
diffus
infiltr
ms
subject
tertiari
lymphoid
follicl
secondaryprogress
ms
spm
patient
author
also
demonstr
mening
follicl
harbor
epsteinbarr
viru
ebv
find
reproduc
other
nevertheless
ebv
remain
one
best
document
environment
link
ms
possibl
causal
role
despit
wealth
observ
data
remain
unclear
whether
b
cell
deplet
therapi
must
also
deplet
intrathec
b
cell
addit
peripher
b
cell
achiev
efficaci
similarli
exact
function
intrathec
b
cell
modul
ms
sever
phenotyp
unknown
analysi
intrathec
b
cell
function
whether
antigenpres
abil
abil
costimul
cell
produc
solubl
factor
preclud
low
number
b
cell
cerebrospin
fluid
csf
current
technolog
possibl
isol
hundr
b
cell
singl
ms
patient
lumbar
punctur
thu
phenotyp
analys
csf
b
cell
perform
far
focus
limit
number
surfac
marker
studi
demonstr
significantli
higher
frequenc
csf
b
cell
plasmablast
patient
ms
inflammatori
neurolog
diseas
oind
comparison
noninflammatori
neurolog
diseas
nind
control
examin
function
properti
intrathec
b
cell
optim
procedur
transform
csf
b
cell
ebv
blindli
analyz
cytokin
secret
larg
number
intrathec
b
cell
line
bcl
deriv
pilot
valid
cohort
describ
paper
studi
carri
accord
recommend
institut
review
board
irb
nation
institut
health
nih
protocol
approv
nih
combin
neurosci
irb
subject
gave
written
inform
consent
accord
declar
helsinki
appli
optim
ebvtransform
procedur
prospectivelyacquir
untreat
patient
present
diagnost
workup
cn
neuroimmunolog
disord
screen
nih
pm
clinic
trial
nih
protocol
comprehens
multimod
analysi
neuroimmunolog
diseas
central
nervou
system
clinicaltrialsgov
identifi
tabl
supplement
inform
elig
subject
age
clinic
neuroimag
evid
immunemedi
cn
damag
healthi
volunt
hv
cn
diseas
risk
factor
immunemedi
system
cn
diseas
patient
underw
diagnost
workup
previous
detail
ms
diagnos
base
revis
mcdonald
diagnost
criteria
prospectivelyenrol
subject
code
csf
sampl
process
blindli
csf
cell
extract
centrifug
g
min
within
min
csf
collect
ebv
immort
protocol
use
pilot
cohort
june
june
subject
lack
blood
contamin
ie
csf
minimum
csf
leukocyt
avail
immort
protocol
b
use
valid
cohort
collect
juli
februari
subject
without
blood
contamin
minimum
csf
leukocyt
immort
irradi
rd
nih
cell
seed
plate
cell
per
well
day
schedul
csf
acquisit
achiev
confluenc
csf
cell
count
cocultur
nih
cell
csf
cellswel
b
cell
media
fb
penicillinstreptomycin
lglutamin
contain
cpg
oligonucleotid
odn
invivogen
san
diego
usa
ngml
cyclosporin
sigmaaldrich
st
loui
usa
ebv
supernat
extract
confluent
marmoset
leukocyt
cell
line
atcc
manassa
usa
optim
condit
csf
b
cell
immort
determin
extens
preliminari
experi
use
protocol
previous
describ
immort
peripher
b
cell
subject
larger
number
csf
cell
proport
well
seed
cellswel
grow
cell
cluster
transfer
week
progress
larger
volum
fresh
b
cell
media
approxim
million
immort
csf
b
cell
obtain
cryopreserv
function
analys
perform
parallel
immort
bcl
instead
seed
multipl
well
csf
cellswel
valid
cohort
seed
wellssubject
csf
cellswel
plate
ie
increas
number
csf
cell
subject
larger
number
avail
csf
cell
thaw
overnightrest
bcl
evalu
surfac
express
costimulatori
activ
marker
intracellular
cytokin
stain
icc
perform
describ
briefli
bcl
activ
phorbol
pma
nm
ionomycin
presenc
brefeldin
per
cell
golgiplug
bd
bioscienc
san
jose
usa
h
stain
surfac
marker
bcl
fix
permeabil
stain
intracellular
cytokin
data
acquir
lsr
ii
analyz
facsdiva
softwar
bd
bioscienc
follow
mous
antihuman
monoclon
antibodi
use
bcl
phenotyp
bd
franklin
lake
usa
bd
bd
apc
bd
alexa
fluor
ebiosci
san
diego
usa
bd
ebiosci
bd
bd
bd
bd
r
system
inc
minneapoli
usa
r
system
inc
bd
bd
also
use
rat
antihuman
monoclon
antibodi
bd
efluor
ebiosci
cryopreserv
csf
bcl
thaw
cultur
week
b
cell
media
penicillinstreptomycin
gentamicin
lglutamin
lonza
basel
switzerland
fetal
bovin
serum
gemini
bioproduct
west
sacramento
usa
cell
resuspend
xvivo
media
lonza
count
hemocytomet
lw
scientif
lawrencevil
usa
resuspend
cellsml
aliquot
also
use
proport
liveb
cell
count
use
flow
cytometri
see
remain
cell
seed
wellplat
b
cellswel
either
unstimul
control
stimul
pma
nm
ionomycin
concentr
optim
preliminari
experi
maxim
cytokin
product
h
cultur
supernat
centrifug
aliquot
frozen
elisa
assay
object
quantifi
number
live
b
cell
gener
supernat
elisa
develop
flowcytometrybas
assay
figur
aliquot
hemocytometercount
bcl
cellsml
resuspend
propidium
iodid
pi
stain
dyingdead
cell
one
million
apc
calibr
fluoresc
particl
spherotm
spherotech
lake
forest
usa
ad
bcl
proport
enumer
bcl
differ
subject
one
lot
bead
use
entir
studi
serial
dilut
pistain
bcl
apc
bead
mixtur
analyz
flow
cytomet
deriv
linear
regress
model
live
pi
neg
b
cell
per
apc
bead
util
proport
normal
b
cell
differ
subjectsexperi
figur
supernat
stimul
csf
bcl
analyz
interleukin
il
tumor
necrosi
factor
tnf
lymphotoxin
lt
granulocyt
macrophag
coloni
stimul
factor
gmcsf
use
vplex
meso
scale
discoveri
platform
elisa
meso
scale
diagnost
rockvil
usa
per
manufactur
protocol
addit
develop
vascular
endotheli
growth
factor
vegf
vegfc
assay
de
novo
use
antibodi
r
system
inc
tabl
defin
assay
manufactur
detect
limit
intraassay
variabl
pilot
studi
assay
suggest
supernat
unstimul
control
b
cell
contain
measur
level
cytokin
therefor
stimul
bcl
condit
analyz
exclus
diagnost
code
ie
relapsingremit
ms
rrm
spm
primaryprogress
ms
ppm
hv
nind
oind
broken
function
data
acquir
gender
spread
diagnost
categori
evalu
chisquar
test
differ
demograph
clinic
csf
data
diagnost
categori
assess
use
kruskalw
analysi
varianc
rank
follow
dunn
test
adjust
multipl
comparison
differ
ebv
transform
rate
assess
binomi
proport
test
betweengroup
comparison
pilot
cohort
assess
use
kruskalw
analysi
varianc
rank
follow
multipl
adjust
dunn
multipl
comparison
test
valid
cohort
fit
linear
mix
model
diagnosi
fix
effect
subject
random
effect
allow
us
test
differ
diagnost
group
account
bcl
gener
csf
sampl
assess
group
differ
mix
model
use
analysi
varianc
anova
follow
pairwis
comparison
leastsquar
mean
model
tukey
adjust
pairwis
multipl
comparison
differ
diagnost
categori
observ
verifi
oneway
ttest
assess
groupwis
differ
result
p
merg
logic
pilot
cohort
merg
oind
nind
neurolog
diseas
ond
valid
cohort
merg
hvnind
combin
ppm
spm
pm
cohort
boxcox
transform
appli
biomark
variabl
nonnorm
distribut
shapirowilk
test
use
test
normal
residu
sa
version
graphpad
prism
version
r
version
use
analys
p
use
signific
level
correl
cytokin
pilot
cohort
assess
pearson
correl
coeffici
valid
cohort
use
spearman
correl
coeffici
bonferroni
pvalu
adjust
assess
correl
cytokin
concentr
ms
diseas
sever
scale
msdss
new
sensit
measur
ms
diseas
sever
averag
number
csf
cell
seed
per
patient
similar
ms
control
vs
ns
likewis
number
seed
well
per
patient
compar
two
cohort
vs
ns
gener
least
bcl
ms
patient
contrast
obtain
csf
bcl
ond
control
p
comparison
ms
quantifi
transform
effici
number
seed
csf
cell
requir
obtain
one
bcl
transform
effici
control
group
averag
bcl
per
seed
csf
cell
oind
nind
ns
transform
effici
almost
time
higher
ms
group
reach
bcl
per
seed
csf
cell
p
effici
immort
correl
weakli
csf
cell
count
spearman
p
csf
igg
index
spearman
p
csf
bcl
express
high
level
bcl
almost
posit
express
costimulatori
molecul
observ
signific
correl
surfac
express
pearson
r
p
figur
reflect
synchron
express
transit
b
cell
cytokin
examin
none
bcl
produc
detect
level
transform
growth
factor
tgf
bcl
produc
low
level
interferon
ifn
product
resid
mostli
classswitch
memori
b
cell
observ
signific
correl
proport
cell
ebvtransform
bcl
proport
cell
pearson
r
p
figur
major
bcl
produc
detect
level
vegf
secret
resid
mostli
transit
b
cell
proport
b
cell
ebvtransform
bcl
correl
moder
igm
express
pearson
r
p
figur
highli
express
pearson
r
p
figur
transit
b
cell
repres
minor
csf
bcl
remain
cytokin
preferenti
express
distinct
b
cell
phenotyp
major
csf
b
cell
memori
b
cell
includ
memori
tissuebas
b
cell
express
cell
activ
marker
gener
lack
igm
express
pearson
r
p
figur
instead
hallmark
naiv
b
cell
pearson
r
p
figur
strongli
coexpress
b
cell
evidenc
strong
correl
pearson
r
p
figur
unblind
diagnost
code
observ
bcl
deriv
control
patient
nind
oind
bcl
patient
ppm
remain
bcl
patient
rrm
bcl
ms
patient
significantli
higher
express
comparison
bcl
control
figur
differ
surfac
marker
reach
statist
signific
similarli
signific
differ
ms
patient
control
resid
higher
product
vegf
bcl
deriv
ms
patient
figur
final
bcl
deriv
ppm
produc
significantli
higher
amount
compar
bcl
rrm
patient
figur
limit
pilot
cohort
significantli
lower
ebv
transform
effici
control
sampl
anticip
led
small
number
control
bcl
similarli
number
bcl
deriv
pm
subject
low
rais
possibl
statist
signific
increas
secret
observ
cohort
may
overestim
therefor
modifi
ebv
immort
method
enhanc
efficaci
seed
csf
cell
singl
well
protocol
b
see
section
method
independ
valid
cohort
preclud
us
valid
differ
ebv
immort
effici
observ
pilot
cohort
low
pvalu
therefor
low
type
ii
error
instead
goal
valid
cohort
transform
suffici
number
bcl
ms
control
pm
patient
disprov
valid
differ
vegf
secret
among
ms
control
relationship
cytokin
ms
phenotyp
also
decid
use
elisa
instead
icc
employ
pilot
cohort
singl
icc
protocol
optim
cytokin
simultan
cytokin
secret
earli
activ
other
secret
late
differ
sensit
protein
transport
inhibitor
monensin
brefeldin
hypothes
inabl
detect
cytokin
commonli
secret
b
cell
pilot
cohort
consequ
technic
problem
icc
elisa
elimin
problem
pose
anoth
result
highli
depend
exact
number
seed
cell
thu
instead
reli
sole
manual
cell
count
implement
unbias
flowcytometrybas
normal
detect
cytokin
concentr
live
b
cell
number
figur
section
method
among
test
subject
addit
studi
vegf
c
isoform
studi
separ
refut
valid
find
pilot
cohort
also
analyz
de
novo
two
addit
cytokin
put
role
ms
gmcsf
tabl
describ
observ
cytokin
secret
result
unblind
diagnost
group
valid
cohort
figur
first
valid
hypothesi
undetect
level
pilot
cohort
consequ
select
icc
procedur
cytokin
readili
detect
elisa
assur
bia
introduc
analyz
csf
bcl
per
subject
ad
random
effect
term
subject
account
varianc
due
repeat
measur
ie
multipl
bcl
singl
subject
normal
cytokin
product
per
million
live
ebvtransform
csf
b
cell
observ
lower
secret
bcl
deriv
rrm
patient
compar
noninflammatori
control
differ
mean
dm
pgml
reach
statist
signific
adjust
multipl
comparison
figur
similarli
saw
differ
among
diagnost
categori
concentr
tabl
cytokin
measur
pilot
cohort
found
signific
differ
among
diagnost
categori
bcell
secret
gmcsf
tabl
surprisingli
observ
lower
product
b
cell
deriv
rrm
patient
compar
diagnost
categori
figur
oind
dm
pgml
p
spm
dm
p
ppm
dm
p
pm
dm
pgml
p
well
hvnind
dm
p
valid
cohort
data
reveal
increas
vegf
secret
ms
b
cell
observ
pilot
cohort
limit
vegfc
figur
furthermor
increas
vegfc
secret
observ
rrm
patient
diagnost
categori
even
though
comparison
oind
reach
statist
signific
dm
pgml
p
valid
cohort
mirror
pilot
cohort
icc
data
b
cell
deriv
pm
patient
secret
highest
concentr
comparison
rrm
oind
noninflammatori
control
although
comparison
rrm
figur
dm
pgml
p
noninflammatori
control
figur
dm
pgml
p
reach
formal
statist
signific
similar
data
obtain
remain
signific
differ
observ
pm
rrm
figur
dm
p
final
ratio
proinflammatori
cytokin
immunoregulatori
cytokin
shown
increas
peripher
blood
ms
patient
compar
hv
also
gener
analog
ratio
proinflammatori
cytokin
test
valid
cohort
observ
trend
lower
ratio
proinflammatori
cytokin
hvnind
group
comparison
subject
intrathec
inflamm
ie
oind
rrm
pm
howev
ratio
achiev
formal
statist
signific
hvnind
compar
ppm
figur
dm
p
pm
figur
dm
p
higher
rrm
cohort
compar
oind
figur
dm
p
demonstr
correl
matrix
figur
valid
cohort
valid
signific
posit
correl
also
strongli
correl
two
addit
cytokin
put
pathogen
role
ms
test
valid
cohort
gmcsf
contrast
vegfc
secret
posit
correl
vegfa
secret
explor
whether
differ
identifi
ms
subject
control
particip
cn
tissu
destruct
assess
correl
patientspecif
csf
b
cell
cytokin
product
measur
elisa
comput
averag
concentr
specif
cytokin
deriv
bcl
isol
specif
subject
new
sensit
model
ms
sever
msdss
msdss
deriv
statist
learn
contrast
older
measur
ms
sever
expand
disabl
statu
scale
edss
base
ms
sever
score
msdss
predict
futur
rate
disabl
progress
msdss
disabl
measur
insensit
discret
edss
replac
much
sensit
statist
learn
optim
continu
disabl
scale
combinatori
weightadjust
disabl
scale
combiwis
addit
disabl
rate
msdss
adjust
patientspecif
treatment
use
mathemat
model
deriv
previous
publish
metaanalysi
random
clinic
trial
diseasemodifi
treatment
ms
final
msdss
model
also
contain
certain
demograph
data
composit
mri
scale
cn
tissu
destruct
comrisctd
msdss
freeli
avail
via
webbas
interphas
http
bielekovalabshinyappsiomsdss
observ
mild
highli
signific
correl
msdss
three
correl
cytokin
gmcsf
figur
studi
present
first
function
analysi
ie
secret
multipl
cytokin
intrathec
b
cell
ms
demonstr
relat
b
cell
clone
popul
cn
compart
ms
includ
csf
valid
evalu
csf
b
cell
repres
popul
strength
studi
resid
applic
highli
standard
protocol
blind
fashion
sizabl
number
ms
patient
control
prospect
collect
singl
institut
critic
also
valid
import
new
find
prospect
acquir
independ
valid
cohort
consid
applic
differ
methodolog
valid
cohort
ie
elisa
oppos
icc
also
strength
studi
demonstr
data
independ
methodolog
constraint
appli
assay
initi
hesit
use
elisa
assay
answer
question
differ
cellular
phenotyp
stem
fact
contrast
icc
output
valu
proport
concentr
cytokin
cell
elisa
measur
sum
cytokin
secret
live
cell
cultur
therefor
elisa
result
crucial
depend
number
seed
cell
manual
cell
count
may
introduc
nois
measur
success
mitig
problem
develop
flowcytometri
base
object
normal
imput
cell
number
among
studi
subject
normal
perform
unblind
diagnost
categori
natur
weak
studi
resid
inabl
measur
cytokin
product
neither
cn
b
cell
csf
b
cell
reli
ebv
transform
vitro
expans
step
nevertheless
csf
biomark
establish
viabl
proxi
inflamm
origin
cn
correl
diseas
patholog
ms
discuss
analog
clonotyp
b
cell
identifi
cn
tissu
csf
individu
patient
regard
ebv
transform
due
limit
number
b
cell
human
csf
irrespect
diagnost
categori
studi
except
intrathec
b
cell
lymphoma
studi
current
technolog
provid
function
inform
ex
vivo
isol
csf
b
cell
rule
possibl
ebv
transform
might
affect
phenotyp
deriv
bcl
howev
blind
written
sop
assur
bia
ebv
transform
vitro
manipul
may
introduc
affect
subject
equal
therefor
explain
observ
valid
differ
among
diagnost
categori
obtain
result
larg
degre
mitig
aforement
concern
studi
reproduc
key
find
previous
publish
ex
vivo
analys
primari
csf
b
cell
significantli
higher
level
costimulatori
molecul
csf
bcl
deriv
ms
patient
comparison
control
trend
lower
product
observ
peripher
blood
b
cell
deriv
ms
patient
comparison
hv
import
novel
find
identifi
current
studi
first
observ
almost
fivefold
higher
effici
ebv
transform
ms
patient
compar
control
may
partial
driven
higher
csf
pleiocytosi
higher
proport
csf
b
cell
ms
compar
nind
patient
hv
true
oind
cohort
oind
ms
subject
similar
proport
csf
b
cell
furthermor
observ
weak
correl
csf
pleiocytosi
csf
igg
index
transform
effici
indic
factor
higher
numberproport
csf
b
cell
ms
cohort
must
underli
differ
transform
effici
higher
transform
effici
caus
higher
ebv
seroposit
observ
subject
ebv
serolog
data
avail
seroposit
tabl
thu
higher
transform
effici
ms
could
mechanist
link
higher
intrathec
ebv
express
previous
report
ms
may
result
defect
cytolyt
activ
csf
cell
toward
ebv
transform
b
cell
describ
peripher
cell
ms
consid
latter
possibl
less
like
use
cyclosporin
transform
protocol
limit
effect
cytotox
cell
final
possibl
ms
suscept
gene
enhanc
ebv
infect
b
cell
rate
immort
hypothesi
consist
experiment
data
present
epidemiolog
data
link
ebv
ms
second
group
novel
find
relat
msspecif
differ
cytokin
phenotyp
intrathec
b
cell
first
find
rather
surpris
decreas
secret
proinflammatori
cytokin
csf
b
cell
rrm
subject
comparison
diagnost
subgroup
find
observ
valid
cohort
studi
secret
icc
pilot
cohort
howev
level
statist
signific
congruenc
find
control
group
make
find
rather
robust
even
absenc
independ
valid
increas
secret
hallmark
genet
autoinflammatori
syndrom
associ
activ
inflammasom
predominantli
cell
innat
immun
secret
regul
caspas
especi
secret
unconvent
enter
classic
endoplasm
reticulum
er
golgi
protein
secret
pathway
instead
secret
requir
format
new
intracellular
compart
call
unconvent
protein
secret
up
induc
stress
depriv
nutrient
addit
secret
link
autophagi
rais
possibl
uniqu
cytokin
secret
phenotyp
rrm
b
cell
may
link
dysfunct
autophagi
pathway
previous
identifi
immun
cell
ms
anim
model
experiment
autoimmun
encephalomyel
eae
howev
must
forget
elisa
measur
differ
secret
consumpt
also
consum
b
cell
especi
regulatori
phenotyp
therefor
enhanc
consumpt
b
cell
deriv
rrm
patient
due
higher
proport
regulatori
b
cell
intrathec
compart
repres
emerg
new
hypothesi
testabl
futur
studi
intriguingli
product
highli
correl
secret
cytokin
express
higher
level
pm
also
correl
ms
sever
measur
msdss
word
patient
higher
b
cell
secret
gmcsf
aggress
ms
character
faster
accumul
disabl
due
collinear
three
cytokin
unclear
whether
independ
contribut
ms
sever
tri
answer
issu
explor
statist
learn
use
either
gener
boost
machin
multipl
linear
regress
assess
whether
complex
model
contain
three
two
cytokin
correl
better
msdss
individu
cytokin
none
model
perform
better
alon
data
shown
suggest
secret
domin
effect
ms
sever
correl
causat
result
gener
hypothesi
futur
studi
b
cell
secret
andor
decreas
consumpt
due
low
proport
regulatori
b
cell
intrathec
compart
contribut
cn
tissu
destruct
ms
remain
differ
phenotyp
ms
intrathec
b
cell
observ
pilot
valid
cohort
found
valid
enhanc
product
vegf
specif
vegfc
vegfa
famili
member
rrm
patient
vegfa
bind
vegf
receptor
express
predominantli
endotheli
cell
surprisingli
vegfa
mediat
effect
vegf
endotheli
cell
stimul
angiogenesi
also
open
epitheli
tight
junction
lead
vascular
edema
contrast
vegfc
bind
third
receptor
express
cell
lymphat
endothelium
thu
mediat
lymphangiogenesi
point
specul
function
consequ
enhanc
vegfc
secret
rrm
b
cell
possibl
lymphangiogenesi
initi
format
lymphoid
aggreg
also
call
tertiari
lymphoid
follicl
found
mening
patient
longstand
ms
link
sever
cn
tissu
destruct
also
found
valid
compar
rrm
patient
bcl
intrathec
b
cell
deriv
pm
patient
produc
higher
amount
two
close
relat
cytokin
view
vegfc
find
describ
import
note
play
import
role
develop
mainten
tertiari
lymphoid
follicl
thu
major
conclus
deriv
analysi
function
phenotyp
csf
b
cell
b
cell
deriv
ms
patient
differ
b
cell
deriv
nonm
control
includ
inflammatori
neurolog
diseas
prolymphangiogen
potenti
vegfc
upregul
b
cell
deriv
earli
rrm
stage
b
cell
pm
instead
secret
higher
concentr
intrigu
topic
futur
investig
similar
msstagespecif
differ
observ
peripher
blood
subset
ms
suscept
gene
use
express
profil
specif
previous
report
ms
suscept
gene
myc
upregul
peripher
blood
rrm
pm
patient
even
mice
overexpress
myc
bcell
progenitor
increas
vegf
product
concurr
stimul
angiogenesi
lymphangiogenesi
possibl
myc
deregul
play
causal
role
observ
vegfc
phenotyp
rrm
progress
patient
contrast
pm
group
rrm
patient
significantli
lower
express
blood
leukocyt
suggest
either
consequ
higher
product
progress
ms
part
neg
feedback
loop
altern
lower
express
receptor
may
caus
lower
consumpt
immun
cell
deriv
progress
ms
clearli
express
gene
translat
protein
chang
diseas
evolut
underli
process
termin
differenti
memori
b
cell
induc
chronic
inflamm
previous
describ
cell
pm
rrm
altern
observ
chang
may
caus
role
eg
patient
increas
product
may
predispos
progress
diseas
two
possibl
address
longitudin
studi
assess
rate
ms
progress
rrm
subject
whose
intrathec
b
cell
produc
high
low
level
conclus
observ
result
suggest
defin
role
intrathec
b
cell
play
ms
contrast
cn
inflammatori
diseas
facilit
compartment
inflamm
cn
tissu
promot
lymphangiogenesi
role
ebv
infect
process
remain
unknown
data
gener
analyz
studi
includ
articl
supplementari
inform
file
author
declar
research
conduct
absenc
commerci
financi
relationship
could
constru
potenti
conflict
interest
